Biocon Limited has informed the Exchange regarding a press release dated November 16, 2021, titled "Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE�� (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection".